![](/img/cover-not-exists.png)
PMS30 SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE
Seyhun, O., Dinç, M., Sevgi, S., Aksun, F., Basegmez, O., Kus, M.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.1574
Date:
November, 2019
File:
PDF, 388 KB
2019